Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2531 |
Eprosartan Mesylate
SKF-108566J,甲磺酸依普罗沙坦 |
RAAS | Endocrinology/Hormones |
Eprosartan Mesylate (SKF-108566J) 是一种具有选择性、竞争性血管紧张素 II 受体拮抗剂,是具有口服活性的非肽。它结合血管紧张素 II 受体,在大鼠和人类肾上腺皮质膜中的IC50值分别为 9.2 nM 和 3.9 nM,可用作降压剂。 | |||
T1461 |
Candesartan
CV 11974,坎地沙坦 |
RAAS | Endocrinology/Hormones |
Candesartan (CV 11974) 是一种血管紧张素II 受体拮抗剂(IC50:0.26 nM)。 | |||
T1615 |
Irbesartan
厄贝沙坦,SR-47436,BMS-186295 |
Apoptosis; RAAS | Apoptosis; Endocrinology/Hormones |
Irbesartan (SR-47436) 是一种 1 型血管紧张素 II 受体拮抗剂,IC50为1.3 nM。 | |||
T13390 |
ZD 7155 hydrochloride
|
RAAS | Endocrinology/Hormones |
ZD 7155 hydrochloride 是血管紧张素II 受体1型 (AT1 receptor) 拮抗剂。 | |||
T0215 |
Losartan potassium
DuP-753 potassium,洛沙坦钾,氯沙坦钾,MK 954,DuP 753 |
RAAS | Endocrinology/Hormones |
Losartan potassium (DuP-753 potassium) 是一种血管紧张素 II 受体 1 型(AT1)拮抗剂,能够与血管紧张素 II 与 AT1 的结合竞争,其 IC50=20 nM。 | |||
T14337 |
Buloxibutid
AT2 receptor agonist C21 |
RAAS | Endocrinology/Hormones |
Buloxibutid (AT2 receptor agonist C21) 是一种新型且具有选择性小分子 angiotensin II AT2 receptor (血管紧张素 II AT2 受体)激动剂,对 AT2 受体和 AT1 受体的 Ki 值分别为 0.4 nM 和 10 μM。 | |||
T2400 |
Candesartan Cilexetil
TCV-116,坎地沙坦酯,坎地沙坦西酯 |
Apoptosis; RAAS | Apoptosis; Endocrinology/Hormones |
Candesartan Cilexetil (TCV-116) 是一种血管紧张素II 拮抗剂,可用于治疗高血压。 | |||
T35834L |
(Sar¹)-Angiotensin II acetate
|
RAAS | Endocrinology/Hormones |
(Sar¹)-Angiotensin II acetate 是血管紧张素 II 的类似物,是血管紧张素 AT1 受体的特异性激动剂。它与富含脑膜的颗粒结合,Kd 为 2.7 nM。它可以刺激胚胎鸡肌细胞中的蛋白质合成和细胞生长。 | |||
TP2158L1 |
TRV-120027 acetate (1234510-46-3 free base)
|
RAAS; Arrestin | Endocrinology/Hormones; GPCR/G Protein |
TRV-120027 acetate (1234510-46-3 free base) 是 1 型血管紧张素 II 受体(AT1 受体)的 β-arrestin-1 偏向激动剂,可与 ß-arrestins 结合,同时阻断 G 蛋白信号传导。 | |||
T0215L |
Losartan
DuP-753,氯沙坦,洛沙坦 |
RAAS | Endocrinology/Hormones |
Losartan (DuP-753) 是一种血管紧张素II 受体拮抗剂,能够与血管紧张素II 竞争性结合AT1受体(IC50:20 nM)。 | |||
T1518 |
Olmesartan Medoxomil
奥美沙坦酯,CS 866,Benicar |
RAAS | Endocrinology/Hormones |
Olmesartan Medoxomil (Benicar) 是血管紧张素 (angiotensin AT1) 受体选择性抑制剂(IC50:66.2 μM)。 | |||
T2531L |
Eprosartan
KF-108566J free base,Teveten |
RAAS | Endocrinology/Hormones |
Eprosartan (SKF-108566J free base) 是一种具有选择性和竞争性的非肽类血管紧张素II受体拮抗剂,对AT1受体亚型具有高亲和力,可用作降压剂。Eprosartan 对血管紧张素 II 受体有抑制作用,在大鼠和人类肾上腺皮质膜中的 IC50 值分别为 9.2 nM 和 3.9 nM。 | |||
T21591 |
1H-1-ethyl Candesartan Cilexetil
|
Others | Others |
1H-1-ethyl Candesartan Cilexetil 是 Candesartan cilexetil 批量合成中的一种工艺相关杂质,坎地沙坦酯是一种强效、长效和选择性血管紧张素 II 1 型受体 (AT1) 拮抗剂。 | |||
T19930 |
Nitrosoglutathione
S-Nitrosoglutathione,S-亚硝基谷胱甘肽,SNOG,Glutathione thionitrite,GSNO |
RAAS; NO Synthase | Endocrinology/Hormones; Immunology/Inflammation |
Nitrosoglutathione (GSNO) 是一种外源性的 NO 供体,是大鼠酒精脱氢酶III 类同工酶的底物,能够减少脑血管紧张素II 依赖性及非依赖型的 AT1 受体反应。 | |||
T8560 |
Angiotensin II human acetate
Ang II acetate,DRVYIHPF acetate,Angiotensin II acetate,血管紧张素II |
Apoptosis; RAAS | Apoptosis; Endocrinology/Hormones |
Angiotensin II human acetate (DRVYIHPF acetate) 是血管收缩剂,是肾素/血管紧张素系统的主要生物活性肽,在调节人类血压中起着核心作用。它刺激交感神经刺激,增加醛固酮生物合成和肾脏活动。它诱导血管平滑肌细胞生长,也诱导细胞凋亡。它通过 LOX-1 依赖的氧化还原敏感途径诱导内皮细胞毛细血管形成。 | |||
T2322 |
Fimasartan
非马沙坦,BR-A-657,Kanarb |
Apoptosis; RAAS | Apoptosis; Endocrinology/Hormones |
Fimasartan (BR-A-657) 是血管紧张素受体 AT1 非肽类拮抗剂,用于研究高血压和心力衰竭。 | |||
T10323 |
Angiotensin II (3-8), human TFA
|
RAAS | Endocrinology/Hormones |
Angiotensin II (3-8), human (TFA) is an angiotensin AT1 receptor agonist with less activity. | |||
T5824 |
Angiotensin II (3-8), human
Angiotensin IV |
RAAS | Endocrinology/Hormones |
Angiotensin II (3-8), human 是活性稍弱的血管紧张素AT1受体激动剂。 | |||
T70225 |
L-159884
|
||
L-159884 is a radiolabelled, nonpeptide angiotensin II antagonist that is useful for angiotensin II, AT1 receptor imaging | |||
T31845 |
Forasartan
SC52458,SC 52458,SC-52458 |
||
Forasartan is a non - peptide angiotensin II receptor antagonist with antihypertensive activity. Forasartan and angiotensin II compete to bind AT1 receptor subtypes in vascular smooth muscle, thereby blocking angiotensin II-mediated vasoconstriction, lead | |||
T13125 | TD-0212 | Others | Others |
TD-0212 is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP). | |||
T13125L | TD-0212 TFA | Others | Others |
TD-0212 TFA is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP). | |||
T29207 |
ZD 7155
ZD 7155,ZD-7155 |
||
ZD 7155 hydrochloride is a potent and selective competitive antagonist for the angiotensin II type 1 (AT1) receptor. It displaces [125I]-angiotensin II binding in guinea pig adrenal gland membranes with an IC50 value of 3.8 nM. | |||
T11675 |
Irbesartan-d4
厄贝沙坦 D4,SR-47436 D4,BMS-186295 D4 |
Others | Others |
Irbesartan D4, a deuterium-labeled variant of Irbesartan, is a highly potent and specific antagonist of the angiotensin II type 1 (AT1) receptor. | |||
T11870 |
Losartan D4
氯沙坦 D4,DuP-753 D4 |
Others | Others |
Losartan D4, the deuterium-labeled version of Losartan, functions as an angiotensin II receptor antagonist. It inhibits the interaction between angiotensin II and AT1 receptors by competing for binding, achieving an IC50 value of 20 nM. | |||
T68890 |
Desvaleryl Valsartan
|
||
Desvaleryl valsartan is a potential impurity found in commercial preparations of the angiotensin II type 1 (AT1) receptor antagonist valsartan. It is a degradation product formed under acidic conditions. | |||
T35725 |
4-hydroxy Valsartan
|
||
4-hydroxy Valsartan is a major metabolite of the angiotensin II type 1 (AT1) receptor antagonist valsartan . It reduces platelet aggregation induced by epinephrine and collagen but not ADP in human whole blood. | |||
T14672 | BMS-248360 | Others | Others |
BMS-248360 is a potent and orally active dual antagonist of both angiotensin II receptor (AT1) and endothelin A (ETA) receptor. With Kis of 10 nM and 1.9 nM for hAT1 and hETA receptor, respectively. BMS-248360 shows hypertensive effects[1]. | |||
T15208 |
Elisartan
HN 65021 |
Others | Others |
Elisartan is a non-peptide pro-drug of angiotensin II AT1 receptor antagonist HN-12206. It also shows anti-hypertension activities. | |||
T35642 | Tritylolmesartan Medoxomil | ||
Tritylolmesartan medoxomil is an intermediate in the synthesis of olmesartan medoxomil , a prodrug form of the angiotensin II receptor 1 (AT1) antagonist olmesartan .1 1.Hanumantha Rao, B., Subramanyeswara Rao, I.V., Ravi Kanth, V., et al.A competent and commercially viable process for the synthesis of the anti-hypertensive drug olmesartan medoxomilSci. Pharm.83(3)465-478(2015) | |||
T35600 |
NO-Losartan A
|
||
Angiotensin II is a hormone that plays an important role in regulating blood pressure. Elevated levels of angiotensin II are implicated in inducing and maintaining hypertension, and also in the development of atherosclerosis. Both of these effects are mediated by the angiotensin II type 1 (AT1) receptor. Losartan is a mammalian AT1 receptor antagonist with a Ki value of 5-20 nM. In humans, losartan effectively controls hypertension while protecting renal function. Nitric oxide (NO) causes vasodi... | |||
T70932 | L6H9 | ||
L6H9 is a novel inhibitor of myeloid differentiation factor 2 (MD2), suppressing HG-induced expression of ACE and AT1 receptor and Angiotensin II (AngII) production in renal NRK‐52E cells, resulting in the decrease in fibrosis markers such as TGF-β and collagen IV. | |||
T36006 |
Olmesartan medoxomil impurity C
|
||
Olmesartan medoxomil impurity C is an Olmesartan medoxomil impurity. Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC50 of 66.2 μM. [1]. Senda A, et al. Effects of Angiotensin II Receptor Blockers on Metabolism of Arachidonic Acid via CYP2C8. Biol Pharm Bull. 2015;38(12):1975-9. [2]. Shah S, et al. Simultaneous Quantitative Analysis of Olmesartan Medoxomil and Amlodipine Besylate in Plasma by High-performance Liquid Chromatography Technique. J Young Phar... | |||
T79267 |
Antihypertensive agent 3
|
||
Antihypertensive agent 3 (compound 4a) 是一种针对血管紧张素 II 受体 1(AT1) 的拮抗剂,其在自发性高血压大鼠(SHRs)的模型中表现出显著的降压效果。 |